Ann: LCT Strategy Update, page-43

Given this is on the front page of our website - Our lead product, NTCELL^®

I would hope that the information they received from the 52 week data for the first two cohorts was in fact positive; otherwise you would have a strong argument of why did they in fact continue to this point ? The November results were poor to say the least (mainly due to only being a 26 week read out IMO) and so if subsequently the 52 week data received in December 2017 was also poor then IMO the entire trial should have been halted at that point?

First to admit, I am no biotech expert, but from a business perspective if both lots of data for 26 week and 52 week were poor you should probably discontinue the trial and call it a day.... move resources into other areas - just sayin' ?

Anywhoo ... not long to wait now - Tuesday according to Assen ... GLTAH